抗 TNF 治疗强直性脊柱炎的疗效和安全性：一项真实世界研究。
Effectiveness and safety of anti-TNF therapy for ankylosing spondylitis: a real-world study.
机构信息
Department of Social Pharmacy, College of Pharmacy, Federal University of Minas Gerais, President Antônio Carlos Avenue, Campus Pampulha, Belo Horizonte, Minas Gerais 6627, Brazil.
Health Assessment, Technology & Economy Group, Center for Exact, Natural & Health Sciences, Federal University of Espírito Santo, Alto Universitário S/N, Guararema, Alegre, Espírito Santo, Brazil.
出版信息
J Comp Eff Res. 2021 Apr;10(6):509-517. doi: 10.2217/cer-2020-0275. Epub 2021 Mar 17.
To evaluate the effectiveness and safety of anti-TNF drugs for ankylosing spondylitis. A prospective cohort study was performed at a pharmacy in the Brazilian Public Health System. Effectiveness by Bath Ankylosing Spondylitis Disease Activity Index, functionality by Health Assessment Questionnaire Disability Index, quality of life by European Quality of Life Five-Dimensions and safety was assessed at 6 and 12 months of follow-up. About 160 patients started the treatment with adalimumab, etanercept or infliximab. There was a statistically significant improvement in disease activity, functionality and quality of life at 6 and 12 months (p < 0.05). This real-world study has shown that anti-TNF drugs are effective and well tolerated for ankylosing spondylitis patients.
评估抗 TNF 药物治疗强直性脊柱炎的疗效和安全性。在巴西公共卫生系统的一家药房进行了一项前瞻性队列研究。通过巴斯强直性脊柱炎疾病活动指数评估疗效，通过健康评估问卷残疾指数评估功能，通过欧洲生活质量五维度评估生活质量，并在随访 6 个月和 12 个月时评估安全性。大约 160 名患者开始接受阿达木单抗、依那西普或英夫利昔单抗治疗。在 6 个月和 12 个月时，疾病活动度、功能和生活质量均有统计学意义上的显著改善（p<0.05）。这项真实世界的研究表明，抗 TNF 药物对强直性脊柱炎患者有效且耐受性良好。
Zotero 插件